Clarus Wealth Advisors Invests $273,000 in Stryker Co. (NYSE:SYK)

Clarus Wealth Advisors bought a new position in shares of Stryker Co. (NYSE:SYK - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund bought 753 shares of the medical technology company's stock, valued at approximately $273,000.

Several other large investors also recently bought and sold shares of SYK. J. W. Coons Advisors LLC lifted its holdings in Stryker by 0.7% during the 4th quarter. J. W. Coons Advisors LLC now owns 3,653 shares of the medical technology company's stock worth $1,315,000 after buying an additional 26 shares during the last quarter. Mascoma Wealth Management LLC boosted its holdings in shares of Stryker by 22.7% in the 4th quarter. Mascoma Wealth Management LLC now owns 146 shares of the medical technology company's stock valued at $53,000 after buying an additional 27 shares in the last quarter. Opal Wealth Advisors LLC raised its stake in Stryker by 1.6% during the 4th quarter. Opal Wealth Advisors LLC now owns 1,816 shares of the medical technology company's stock worth $654,000 after acquiring an additional 28 shares in the last quarter. Lindbrook Capital LLC grew its holdings in shares of Stryker by 2.0% during the fourth quarter. Lindbrook Capital LLC now owns 1,407 shares of the medical technology company's stock worth $507,000 after purchasing an additional 28 shares during the last quarter. Finally, JFS Wealth Advisors LLC grew its holdings in shares of Stryker by 4.4% during the fourth quarter. JFS Wealth Advisors LLC now owns 687 shares of the medical technology company's stock worth $247,000 after purchasing an additional 29 shares during the last quarter. Hedge funds and other institutional investors own 77.09% of the company's stock.

Analysts Set New Price Targets

SYK has been the subject of a number of research analyst reports. Sanford C. Bernstein set a $450.00 target price on Stryker in a research report on Monday, May 5th. Truist Financial boosted their price objective on Stryker from $390.00 to $400.00 and gave the company a "hold" rating in a research note on Monday, May 5th. BTIG Research set a $403.00 price objective on Stryker and gave the company a "buy" rating in a report on Monday, April 14th. Evercore ISI dropped their price objective on shares of Stryker from $400.00 to $390.00 and set an "outperform" rating on the stock in a research note on Friday, May 2nd. Finally, Citigroup reissued a "buy" rating and issued a $455.00 price objective (up from $443.00) on shares of Stryker in a research note on Thursday, May 22nd. Five research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Stryker currently has an average rating of "Moderate Buy" and an average target price of $427.30.

Insider Transactions at Stryker

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the business's stock in a transaction dated Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the completion of the sale, the director now owns 3,417,326 shares of the company's stock, valued at approximately $1,288,195,208.96. The trade was a 5.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 5.90% of the company's stock.

Stryker Trading Up 0.5%

NYSE SYK traded up $1.86 during trading hours on Wednesday, hitting $382.87. 838,108 shares of the company's stock were exchanged, compared to its average volume of 1,335,074. The business's 50 day moving average is $369.31 and its 200-day moving average is $376.06. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. Stryker Co. has a 12-month low of $314.93 and a 12-month high of $406.19. The firm has a market capitalization of $146.14 billion, a P/E ratio of 49.34, a price-to-earnings-growth ratio of 2.93 and a beta of 0.93.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.84 earnings per share for the quarter, topping the consensus estimate of $2.73 by $0.11. Stryker had a net margin of 13.25% and a return on equity of 23.58%. The business had revenue of $5.87 billion for the quarter, compared to analyst estimates of $5.68 billion. During the same period in the prior year, the firm posted $2.50 EPS. The company's revenue was up 11.9% on a year-over-year basis. As a group, analysts anticipate that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Monday, June 30th will be paid a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, June 30th. This represents a $3.36 annualized dividend and a dividend yield of 0.88%. Stryker's dividend payout ratio is presently 45.41%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.